Recent News

• 03.30.2026 - Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
• 03.02.2026 - Palisade Bio Announces Participation in Two Upcoming Investor Conferences
• 02.23.2026 - Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
• 02.17.2026 - Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
• 02.09.2026 - Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
• 02.05.2026 - Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Recent Filings

• 03.20.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2026 - 4 Statement of changes in beneficial ownership of securities